Helix BioPharma Corp.
TSX:HBP.TO · Toronto Stock Exchange
-$0.07 today
Vol 0.00M · Avg 0.00M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.4%
avg 6264.2%
ROIC
-33.9%
avg 6432.1%
ROA
-27.7%
avg -377.0%
Analysis
ROA is currently the strongest return metric at -27.7% versus its period average of -377.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas Mehrling | CEO & Chief Medical Officer | $318,920.00 | — | — | — | — |
Rohit Babbar | Chief Financial Officer | $243,768.00 | — | — | — | — |
Veronika Kandziora | Chief Operating Officer | $232,241.00 | — | — | — | — |
Davide Guggi | Chief Technology Officer | $213,599.00 | — | — | — | — |
Jacek Antas | Chairman & Corporate Secretary | $100,000.00 | — | — | — | — |
Helen Middleton | General Counsel | — | — | — | — | — |
Natalia L. Butterworth | Corporate Secretary | — | — | — | — | — |
Jessica Kourniaktis DPHIL | Director of Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A0 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Quipt Home Medical Corp.
QIPT.TO
$221.44M
Cannara Biotech Inc.
LOVE.V
$181.03M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
Cybin Inc.
CYBN.NE
$157.10M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
Satellos Bioscience Inc.
TSX:MSCL.TO
$125.68M
Sernova Corp.
TSX:SVA.TO
$53.90M
Resverlogix Corp.
RVX.TO
$31.70M
Medicenna Therapeutics Corp.
MDNA.TO
$29.90M
Who manages HBP.TO?
Helix BioPharma Corp. (HBP.TO) lists 8 active executives. The top listed executive is Thomas Mehrling, CEO & Chief Medical Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.